It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering ...

Company to present an interim update of data from the MANIFEST clinical trial of CPI-0610 at ASCO on June 3 and at EHA on June 15 Related investor event at ASCO to be held on June 4 CAMBRIDGE, Mass., ...

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its previously announced cash tender offer for ...

Shares of Constellation Pharmaceuticals Inc. traded 65% higher after the company reported it entered into an agreement to be acquired by MorphoSys AG in an all-cash transaction for $34 per share.

Constellation Pharmaceuticals, Inc. (CNST) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Constellation Pharmaceuticals Inc., a biotech startup ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Constellation Pharmaceuticals Inc. has announced a ...

CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering ...